Saturday, June 24, 2017

In Penn. Parties To Risperdal Mass Tort Gynecomastia Case To Meet Next Month

Posted on June 23, 2017 by Monika Donimirska

Parties to Pennsylvania Risperdal Gynecomastia Lawsuits Set to Meet Next Month to Discuss Status of Mass Tort Litigation, Bernstein Liebhard LLP Reports 

NEW YORK, June 23, 2017 /PRNewswire/ -- Thousands of Risperdal lawsuits involving the antipsychotic medication's alleged potential to cause gynecomastia (male breast growth) continue to move forward in a mass tort litigation now underway in Pennsylvania's Philadelphia Court of Common Pleas. According to a posting on the website for the Philadelphia Complex Litigation Center, the Court will convene a meeting on July 11th, 11:30 p.m. EST, to discuss the status of the Risperdal litigation. (Case No. 130600861)

"Our Firm is representing many men and boys who allegedly developed female-like breasts due to treatment with Risperdal. We will continue to monitor the Pennsylvania litigation closely for any developments that could impact our clients' cases," said Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to provide free legal reviews to men and boys who were diagnosed with gynecomastia allegedly related to their use of Risperdal.

Risperdal Gynecomastia Allegations

Court records indicate that Johnson & Johnson and its Janssen Pharmaceuticals subsidiary have been named defendants in more than 5,800 Pennsylvania Risperdal lawsuits. In May, Johnson & Johnson reported that at least 16,900 product liability claims have been filed in courts nationwide over the medication's alleged side effects. Gynecomastia plaintiffs claim that the drugs' manufacturers concealed data linking Risperdal to excessive male breast growth and failed to provide the public with appropriate warnings regarding this risk.

The Pennsylvania litigation has convened 8 Risperdal trials since early 2015. So far, juries have ruled for plaintiffs in four cases, awarding damages ranging from $500,000 to $70 million. Confidential Risperdal settlements have also been reached in some gynecomastia lawsuits just prior to trial. Bernstein Liebhard LLP continues to provide free legal reviews to alleged victims of Risperdal and gynecomastia. To learn more about filing a Risperdal lawsuit, please contact Bernstein Liebhard LLP by visiting the Firm's website, or by calling 800-511-5092.

Thank You satprnews.

No comments: